GeneDx Holdings Business Summary

GeneDx Holdings Corp. (WGS) operates a transaction-based business model centered on clinical genomic diagnostics, generating revenue primarily through high-complexity whole exome and genome sequencing (WES/WGS) services. The company’s primary business segments are categorized into its core Exome and Genome testing—which accounts for the majority of its revenue growth—and a broader menu of genetic tests covering pediatric neurology, hereditary cancer, cardiology, and prenatal care. Beyond diagnostic fees, GeneDx leverages its "GeneDx Infinity" platform, one of the world’s largest rare disease genomic datasets, to drive high-margin biopharma partnerships and longitudinal research collaborations. Within the competitive landscape, GeneDx maintains a dominant position in the pediatric and rare disease niche, competing directly with Natera, Myriad Genetics, and Ambry Genetics by focusing on superior diagnostic yield and AI-driven interpretation rather than high-volume reproductive screening. Originally founded in 2000 by NIH scientists Sherri Bale and John Compton, the current corporate entity is the result of a 2022 transformative merger with Sema4, founded by genomic pioneer Eric Schadt. The leadership team is led by CEO Katherine Stueland, formerly the Chief Commercial Officer of Invitae, and CFO Kevin Feeley, who has overseen the company’s path to adjusted net income profitability. Other key executives include COO Bryan Dechairo and Chief Medical Officer Dr. Linda Genen, who joined in early 2026 to lead clinical strategy. The company is backed by a high-pedigree board and investor base, including Chairman Jason Ryan (former CFO of Foundation Medicine), Eli Casdin of Casdin Capital, Keith Meister of Corvex Management, and Thomas Fuchs (Chief AI Officer at Eli Lilly). Notable institutional support remains strong from ARK Investment Management and the Icahn School of Medicine at Mount Sinai.